December 27, 2023
4 min watch
Save
VIDEO: PIM1 kinase inhibitor lowers cytokines in TP-3654 study
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Lindsay A.M. Rein, MD, discussed the phase 1/phase 2 TP-3654 study into relapsed/refractory myelofibrosis, data from which she presented at the ASH Annual Meeting and Exposition.
Rein, a hematologic oncologist at Duke Health, discussed the study, which treated a sample of patients with an oral investigational highly selective PIM1 kinase inhibitor, and which returned data showing reduced cytokine levels.
“It’s a really exciting early phase study with some suggestion of early clinical activity and associated reductions in cytokines when we look at biomarker data,” Rein said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio interview
Disclosures:
Rein reports consulting for AbbVie, CTI Biopharma, Incyte, Merck, Novartis and Sumitomo Pharma, and receiving research funding from Blueprints Medicine, Cogent, Geron, Incyte, Karyopharm, Merck, Novartis, PharmaEssentia, Protagonist and Sumitomo Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.